日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Phase I trial of FOLFIRI in combination with sorafenib and bevacizumab in patients with advanced gastrointestinal malignancies

FOLFIRI联合索拉非尼和贝伐珠单抗治疗晚期胃肠道恶性肿瘤患者的I期临床试验

期刊:Investigational New Drugs
影响因子:2.7
doi:10.1007/s10637-015-0308-5
Hubbard, Joleen M; Kim, George; Borad, Mitesh J; Johnson, Elizabeth; Qin, Rui; Lensing, Janet; Puttabasavaiah, Suneetha; Wright, John; Erlichman, Charles; Grothey, Axel
肿瘤
肿瘤免疫
发表日期：2016
文献求助 收藏

5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial

一项随机对照试验的5年随访结果显示，在接受他莫昔芬治疗后开始服用来曲唑的绝经后乳腺癌女性中，立即使用唑来膦酸与延迟使用唑来膦酸预防骨质流失的效果相当：N03CC（Alliance）试验

期刊:Cancer
影响因子:5.1
doi:10.1002/cncr.29327
Wagner-Johnston, Nina D; Sloan, Jeff A; Liu, Heshan; Kearns, Ann E; Hines, Stephanie L; Puttabasavaiah, Suneetha; Dakhil, Shaker R; Lafky, Jacqueline M; Perez, Edith A; Loprinzi, Charles L
肿瘤
肿瘤免疫
乳腺癌
发表日期：2015
文献求助 收藏